The Texas Tech University Health Sciences Center is conducting a research study that will look at whether calcium, vasopressin, or both early in the course of treatment would help severely injured patients that lose a lot of blood survive their injuries.
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) trial will include approximately 1,050 people aged 18 to 90. Patients who have traumatic injuries with loss of blood may be enrolled by participating emergency medical personnel during their transportation to the hospital or after arrival to University Medical Center Hospital.
CAVALIER is an Exception from Informed Consent (EFIC) trial, meaning that, the trial requires performing a potentially life-saving intervention in people who are too injured to give permission. This study will look at treatment for patients who have a traumatic injury and have lost a lot of blood. These patients are too injured to give permission before receiving the study drug. Permission for continued participation will be obtained from patients once they are able, or from their family members, as soon as possible.
For more information about CAVALIER or to complete an anonymous survey on your thoughts about this EFIC study, please go to http://www.litesnetwork.org/cavalier/ .
This research is supported by DoD contract W81XWH-16-D-0024 W81XWH-22-F-0118. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Department of the Army, Department of Defense or the U.S. Government.
###
Randomized controlled/clinical trial
People